

Correction

Correction: Nerofe+IdDox releases c-Jun from nuclear ST2 to reprogram the immune microenvironment in mtKRAS tumors**Joel Ohana¹, Uziel Sandler^{1,2}, Benjamin A. Weinberg³, Stephen Liu³ and Yoram Devary¹**¹Immune System Key (ISK) Ltd., Jerusalem 9746009, Israel²Department of Bio-Informatics, Lev Academic Center (JCT), Jerusalem 91160, Israel³Ruesch Center for the Cure of Gastrointestinal Cancers, Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC 20007, USA**Published:** April 24, 2026**Copyright:** © 2026 Ohana et al. This is an open access article distributed under the terms of the [Creative Commons Attribution License](#) (CC BY 4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.**This article has been corrected:** The authors of the article have provided a correction for the “Conflicts of Interest” section. The corrected text is shown below.**CONFLICTS OF INTEREST**

Joel Ohana, Uziel Sandler, and Yoram Devary are affiliated with Immune System Key (ISK) Ltd., which is involved in the development of Nerofe, the compound investigated in this study. This affiliation represents a potential competing interest.

Original article: Oncotarget. 2025; 16:848–857. <https://doi.org/10.18632/oncotarget.28820>